

Attorney Docket No.: 10017.200-US

3/A
PATENT
AD
5/28/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schnorr et al

Application No.: To Be Assigned

Group Art Unit: To Be Assigned

Filed: February 16, 2001

Examiner: To Be Assigned

For: Family 44 Xyloglucanases

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, DC 20231

Sir:

Before the above-captioned application is taken up for examination, entry of the following amendment is respectfully requested:

IN THE CLAIMS:

///
Please cancel claims 13-18, 21, 25-27 and 30-32 without prejudice or disclaimer.


REMARKS

This amendment is submitted to cancel claims in order to reduce the filing fee. Applicants submit no new matter is added, and entry of the amendment is respectfully requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: February 16, 2001


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

The assignee of the present application is:


Novozymes A/S
Krogshoejvej 36
DK-2880 Bagsvaerd
Denmark

Applicants request that the assignee information be included in the published patent application.

Please charge the required fee, estimated to be \$710, to Novozymes North America, Inc.,
Deposit Account No. 50-1701. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 16, 2001



Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123